Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mario Gabelli Raises Exposure to Layne Christensen Company (LAYN)

Mario Gabelli‘s GAMCO Investors has disclosed picking up its stake in Layne Christensen Company (NASDAQ:LAYN) to 1.98 million shares, from 1.81 million reported as held at the end of the first quarter of the year. GAMCO’s new stake ammases almost 10% of the company’s common stock. Overall, GAMCO, together with other affiliated funds such as Gabelli Funds and Teton Advisors owns around 3.11 million shares, equal to 15.70% of the Layne Christensen Company (NASDAQ:LAYN)’s common stock.

Mario Gabelli

In the previous round of 13F filings, several other funds revealed ownership of Layne Christensen Company (NASDAQ:LAYN)’s shares. Chuck Royce‘s Royce & Associates held around 1.79 million shares, followed by Peter Schliemann‘s Rutabaga Capital Management with 1.26 million shares, while some other funds reported smaller stakes in the small-cap company. With a market cap of $244.7 million, Layne Christensen Company (NASDAQ:LAYN) is engaged in water management, construction and drilling of water- and sewage-related infrastructure. The company operates primarily in North America, but also conducts works in Africa, Asia, Australia and South America.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!